Literature DB >> 23556036

Amyopathic dermatomyositis complicated by pneumomediastinum.

Randy Tang1, Christian R Millett, Justin J Green.   

Abstract

Dermatomyositis is an inflammatory disease of unclear etiology with characteristic cutaneous and musculoskeletal findings. Amyopathic dermatomyositis is a subtype without musculoskeletal involvement. Many cases of dermatomyositis are associated with underlying malignancy, but pulmonary manifestations can also be seen, the most common of which is interstitial lung disease. Pneumomediastinum is a rare complication that is important for clinicians to recognize, as it may be fatal if left untreated. The sudden onset of facial edema and shortness of breath in the setting of dermatomyositis should raise the suspicion of this condition.

Entities:  

Year:  2013        PMID: 23556036      PMCID: PMC3613273     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  26 in total

1.  [Therapeutic efficacy of cyclosporin A in four cases of amyopathic dermatomyositis with rapidly progressive interstitial pneumonia].

Authors:  Y Ozawa; D Kurosaka; T Yokoyama; N Tajima
Journal:  Ryumachi       Date:  2000-10

2.  Pneumomediastinum and subcutaneous emphysema associated with dermatomyositis.

Authors:  C Korkmaz; R Ozkan; M Akay; T Hakan
Journal:  Rheumatology (Oxford)       Date:  2001-04       Impact factor: 7.580

3.  A 34-year-old man with amyopathic dermatomyositis and rapidly progressive dyspnea with facial swelling. Diagnosis: pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis-associated interstitial lung disease.

Authors:  Christian Powell; Brian Kendall; Richard Wernick; John E Heffner
Journal:  Chest       Date:  2007-11       Impact factor: 9.410

4.  Late-onset pneumomediastinum in dermatomyositis.

Authors:  Karim Z Masrouha; Nadim Kanj; Imad Uthman
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

5.  Spontaneous pneumomediastinum secondary to refractory dermatomyositis successfully treated with rituximab.

Authors:  Martin A Lee; David G Hutchinson
Journal:  Clin Rheumatol       Date:  2010-03-01       Impact factor: 2.980

6.  Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

Authors:  C L Hill; Y Zhang; B Sigurgeirsson; E Pukkala; L Mellemkjaer; A Airio; S R Evans; D T Felson
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

Review 7.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

8.  Dermatomyositis and pulmonary fibrosis associated with anti-Jo-1 antibody.

Authors:  T J Phillips; I M Leigh; J Wright
Journal:  J Am Acad Dermatol       Date:  1987-08       Impact factor: 11.527

9.  Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease.

Authors:  M C Hochberg; D Feldman; M B Stevens; F C Arnett; M Reichlin
Journal:  J Rheumatol       Date:  1984-10       Impact factor: 4.666

Review 10.  Pneumomediastinum in dermatomyositis itself is not a poor prognostic factor: report of a case and review of the literature.

Authors:  Ken Yoshida; Daitaro Kurosaka; Isamu Kingetsu; Kenichiro Hirai; Akio Yamada
Journal:  Rheumatol Int       Date:  2008-02-29       Impact factor: 2.631

View more
  2 in total

1.  Survival analysis and risk factors for mortality in connective tissue disease-associated pneumomediastinum.

Authors:  Lu Zhang; Min Shen; Fengchun Zhang; Fulin Tang
Journal:  Rheumatol Int       Date:  2014-05-29       Impact factor: 2.631

2.  Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis.

Authors:  Mengmeng Zhou; Yan Ye; Ninghui Yan; Xinyue Lian; Chunde Bao; Qiang Guo
Journal:  Clin Rheumatol       Date:  2020-01-15       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.